The SLC22A2 gene is a determinant of hematological toxicity of oxaliplatin in patients with colorectal cancer.

IF 0.9 4区医学 Q4 PHARMACOLOGY & PHARMACY

International journal of clinical pharmacology and therapeutics Pub Date : 2023-01-01 DOI:10.5414/CP204156

Jiayin Chen, Li Wang, Gangling Tong, Jie Ma, Chaoran Liu, Lijun Wang

{"title":"The SLC22A2 gene is a determinant of hematological toxicity of oxaliplatin in patients with colorectal cancer.","authors":"Jiayin Chen, Li Wang, Gangling Tong, Jie Ma, Chaoran Liu, Lijun Wang","doi":"10.5414/CP204156","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the association between polymorphisms in the SLC22A2 gene and the hematological toxicity of oxaliplatin in colorectal cancer (CRC) patients receiving chemotherapy.Materials and methods: A total of 81 patients with colon or rectal cancer were included in the study. The single nucleotide polymorphisms (SNPs) rs3127573, rs316019, and rs1869641 of the SLC22A2 gene were selected for genotyping using the polymerase chain reaction (PCR) and sequence analysis. Oxaliplatin-associated hematological toxicities were evaluated using the Common Toxicity Criteria for Adverse Events (CTCAE, Version 5.0).Results: The rs1869641 genotype was significantly associated with the occurrence of thrombocytopenia (p = 0.047), whereas the rs316019 genotype was significantly associated with severity of leucopenia and neutropenia (p = 0.004 and 0.001, respectively). The rs3127573 genotype was not associated with hematological toxicities arising during chemotherapy with oxaliplatin.Conclusion: It is shown here, for the first time, that the rs316019 gene variant of the SLC22A2 gene may be associated with the hematological toxicity of oxaliplatin. Patients with genotype CA/AA of rs316019 are more likely to develop serious hematological adverse effects.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 1","pages":"1-7"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical pharmacology and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CP204156","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the association between polymorphisms in the SLC22A2 gene and the hematological toxicity of oxaliplatin in colorectal cancer (CRC) patients receiving chemotherapy.

Materials and methods: A total of 81 patients with colon or rectal cancer were included in the study. The single nucleotide polymorphisms (SNPs) rs3127573, rs316019, and rs1869641 of the SLC22A2 gene were selected for genotyping using the polymerase chain reaction (PCR) and sequence analysis. Oxaliplatin-associated hematological toxicities were evaluated using the Common Toxicity Criteria for Adverse Events (CTCAE, Version 5.0).

Results: The rs1869641 genotype was significantly associated with the occurrence of thrombocytopenia (p = 0.047), whereas the rs316019 genotype was significantly associated with severity of leucopenia and neutropenia (p = 0.004 and 0.001, respectively). The rs3127573 genotype was not associated with hematological toxicities arising during chemotherapy with oxaliplatin.

Conclusion: It is shown here, for the first time, that the rs316019 gene variant of the SLC22A2 gene may be associated with the hematological toxicity of oxaliplatin. Patients with genotype CA/AA of rs316019 are more likely to develop serious hematological adverse effects.

查看原文本刊更多论文

SLC22A2基因是奥沙利铂对结直肠癌患者血液学毒性的决定因素。

目的:探讨SLC22A2基因多态性与奥沙利铂在结直肠癌(CRC)化疗患者血液学毒性的关系。材料与方法:共纳入81例结肠癌或直肠癌患者。选择SLC22A2基因的单核苷酸多态性rs3127573、rs316019和rs1869641，采用聚合酶链反应(PCR)和序列分析进行分型。使用不良事件通用毒性标准(CTCAE, 5.0版)评估奥沙利铂相关的血液学毒性。结果:rs1869641基因型与血小板减少的发生显著相关(p = 0.047)， rs316019基因型与白细胞减少和中性粒细胞减少的严重程度显著相关(p = 0.004和0.001)。rs3127573基因型与奥沙利铂化疗期间产生的血液学毒性无关。结论:本研究首次发现SLC22A2基因rs316019基因变异可能与奥沙利铂的血液学毒性有关。rs316019基因型为CA/AA的患者更容易发生严重的血液学不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of clinical pharmacology and therapeutics 医学-药学

CiteScore

1.70

自引率

12.50%

发文量

116

审稿时长

4-8 weeks

期刊介绍： The International Journal of Clinical Pharmacology and Therapeutics appears monthly and publishes manuscripts containing original material with emphasis on the following topics: Clinical trials, Pharmacoepidemiology - Pharmacovigilance, Pharmacodynamics, Drug disposition and Pharmacokinetics, Quality assurance, Pharmacogenetics, Biotechnological drugs such as cytokines and recombinant antibiotics. Case reports on adverse reactions are also of interest.